China Pharma (CPHI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	718.69 k	718.69 k	718.69 k	718.69 k	718.69 k	718.69 k
Cash burn (monthly)	6.88 k	54.27 k	372.64 k	395.35 k	15.65 k	60.60 k
Cash used (since last report)	29.43 k	232.08 k	1.59 mm	1.69 mm	66.94 k	259.16 k
Cash remaining	689.26 k	486.61 k	-875.01 k	-972.13 k	651.76 k	459.53 k
Runway (months of cash)	100.2	9.0	-2.3	-2.5	41.6	7.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

CPHI institutional ownership history Ownership history

26.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	5	-60.0%
Opened positions	0	4	EXIT
Closed positions	3	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	7.00 k	13.97 mm	-99.9%
Total shares	5.16 mm	5.22 mm	-1.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Streeterville Capital	5.16 mm	$0.00	0.0%
First Community Trust Na	30.00	$7.00 k	0.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
XTX Topco	0.00	-28.74 k	EXIT
Baader Bank	0.00	-20.31 k	EXIT
Susquehanna International	0.00	-10.92 k	EXIT
Proequities	0.00	0.00
First Community Trust Na	30.00	0.00	0.0%
Streeterville Capital	5.16 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CPHI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Sep 23	Zhilin Li	Common Stock	Grant	Acquire A	No	No	0.14	13,757,063	1.93 mm	15,138,063

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Pre-Market Session

30 Dec 24

China Pharma Files Prospectus Supplement With The U.S. SEC Under Which The Company May Offer And Sell From Time To Time Shares Of Common Stock, With An Aggregate Offering Price Of Up To $600,000

13 Dec 24

China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission

Press releases

From Benzinga Pro

China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

18 Dec 24

HAIKOU, China, Dec. 18, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty

China Pharma Announces the Entry of "At-The-Market" Equity Offering

13 Dec 24

HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus